This has considerable therapeutic implications as current anti-VEGFA treatments against multiple froms of cancer (Bevacizumab, Avastin®) or diabetic retinopathies and macular degeneration (Ranibizumab, Lucentis®) potentially target both pro- and anti-angiogenic forms of VEGFA [13,22]. The gene discussed is VEGFA; the disease is macular degeneration.